| Literature DB >> 35496738 |
Natália Nobre de Alencar1, Diego Agra de Souza2, Alexandre Alves Lourenço1,2, Raimunda Ribeiro da Silva1,2.
Abstract
Breast sebaceous carcinoma is one of the rarest breast neoplasms, with less than 30 cases reported worldwide. Due to the rarity, the new WHO classification of breast tumors grouped these tumors among the ductal carcinoma. A detailed description of these cases is relevant due to the insufficient knowledge about the prognosis of this neoplasm. We report the clinical, histological, and immunohistochemical characteristics of a case of sebaceous carcinoma of the breast in an 81-year-old woman with a right breast nodule. The tumor was composed of nests of a varying mixture of sebaceous cells with abundant slightly vacuolated cytoplasm, surrounded by smaller oval-to-fusiform cells with eosinophilic cytoplasm without vacuolization. No lymph node metastases were present. The immunohistochemical reactions were positive for GATA3, EMA, CD15, and GCDFP15 (focal staining), and negative for RE, RP, and HER-2. The tumor was classified as triple-negative. Morphologically, the differential diagnoses included skin sebaceous carcinoma, lipid-rich carcinoma, apocrine carcinoma, and glycogen-rich clear cell carcinoma. Most of the previously reported cases were positive for RE and RP, which generally was associated with a better prognosis. However, some cases presented a more aggressive behavior with distant and lymph node metastases.Entities:
Keywords: Adenocarcinoma; Adenocarcinoma Sebaceous; Breast Neoplasms; Carcinoma; Sebaceous Gland Neoplasms
Year: 2022 PMID: 35496738 PMCID: PMC9037860 DOI: 10.4322/acr.2021.365
Source DB: PubMed Journal: Autops Case Rep ISSN: 2236-1960
Figure 1Photomicrograph of the tumor. A, B, C – Lobules of tumor cells with abundant vacuolated cytoplasm, surrounded by more basophilic tumor cells in the periphery of the lobules (HE); D – Clusters of cells without evidence of sebaceous differentiation, indistinguishable from a classic ductal carcinoma (HE).
Figure 2Photomicrograph of the tumor. Immunohistochemical panel. A – Positive expression of EMA in the tumor cells (100 x); B – Positive expression of GATA-3 in the tumor cells (25 x); C – Strongly positive expression of CD15 in the tumor cells with sebaceous differentiation (100 x); D – Focal positivity of GCDFP15 in the tumor Cells (25X)
Summary of the main morphological differences between breast SC (sebaceous carcinoma), skin SC, lipid-rich carcinoma, and glycogen-rich clear cell carcinoma
|
|
|
|
|
| |
|---|---|---|---|---|---|
|
| 2 types | 2 types | +2 types | 2 types | 1 type |
|
| Vacuolated | Vacuolated | Vacuolated, lipid-rich | Granular eosinophilic and/or vacuolated | Clear and abundant, glycogen-rich |
|
| Lobules or nests | Lobules and nests | Irregular | Glandular and tubular | Solid or papillary |
|
| Present (moderate to severe) | Present | Present | Present | Present |
| (Moderate to severe) | (Moderate to severe) | (Moderate to severe) | |||
|
| Absent | Absent | Absent | Absent | Absent |
|
| Generally - | + | |||
|
| - | - | - | - | + |
PAS – Ácido periódico de Schiff.
Clinicopathological summary and follow-up of patients with breast sebaceous carcinoma
|
|
|
|
|
|
|---|---|---|---|---|
|
| 74/F | 5.0 cm | Alive without evidence of disease for 6 months after surgery. | |
|
| 55/M | 5.0 cm | - | Alive without evidence of disease for 10 months after surgery. |
|
| 45/F | 2.5 cm | - | Alive with disease for 96 months after surgery. |
| Skin and bone metastases. | ||||
|
| 46/F | 1.4 cm | Alive without evidence of disease for 6 months after surgery. | |
|
| 63/F | 2 cm | + | |
|
| 50/F | 2 cm | + | Alive without evidence of disease for 24 months after surgery. |
|
| 85/F | 2.5 cm | ||
| Disease recurrence after 10 months after surgery | ||||
|
| 65/F | 1.6 cm | + | Alive without evidence of disease for 27 months after surgery. |
|
| 61/F | 1.7 cm | + | Liver, lung, and bone metastases, pathologic fracture of the femur, arrhythmia. |
| Deceased from the disease 28 months after surgery. | ||||
|
| 66/F | 3 cm | + | Endometrial carcinoma; metastases to the mediastinal and supraclavicular lymph nodes. |
| Alive with disease for 70 months after surgery. | ||||
|
| 25/F | - | Had a child. | |
| Alive without evidence of disease for 75 months after surgery. | ||||
|
| 80/F | 3.5 cm | - | Alive with evidence of disease. |
| Metastatic cervical carcinoma 16 months after surgery. | ||||
|
| 55/F | 6.5 cm | - | Alive without evidence of disease for 13 months after surgery. |
|
| 42/F | 2.5 cm | + | Alive without evidence of disease for 15 months after surgery. |
|
| 74/F | 2.3 cm | - | Alive without evidence of disease for 58 months after surgery. |
|
| 51/F | 2.0 cm | - | |
| Our case | 81/F | 3.4 cm | Alive without evidence of disease for 9 months after surgery | |
|
| 71/F | 1.4 cm | - | Alive without evidence of disease for 18 months after surgery. |
|
| 70/M | 1.7 cm | - | |
|
| 47/F | 1.3 cm | - | Alive without evidence of disease for 16 months after surgery. |
|
| 79/F | 1.5 cm | Alive without evidence of disease for 36 months after surgery | |
|
| 63/F | 1.8 cm | + | |
|
| 65/F | 1.1 cm | + | Refused further treatment. Recurrence disease 4 months after surgery. Died at ninth month of follow-up. |
|
| 71/F | 2.7 cm | - | Alive without evidence of disease for 100 months after surgery. |
|
| 70/M | 1.7 cm | - | Alive without evidence of disease for 2 months after surgery. |
|
| 65/F | 3.0 cm | + | Alive without evidence of disease for 4 months after surgery. |
|
| 53/F | 1.2 cm | - |
LN= lymph nodes; F = Sexo feminino; M = Sexo masculino; - = Negativo para metastases em linfonodo sentinela; + = Positivo para metátastases em linfonodo sentinela.
Summary of immunohistochemical data for breast sebaceous carcinoma
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| + | + | |||||||||||
|
| + | + | - | 16% | |||||||||
|
| + | + | - | 38% | + | - | |||||||
|
| - | - | + | 30% | + | + | + | ||||||
|
| - | - | - | 25% | - | + | |||||||
|
| + | + | - | 30% | + | + | |||||||
| - | - | - | 80% | - | + | ||||||||
| + | + | - | 5% | - | - | ||||||||
| + | + | - | - | + | - | ||||||||
|
| - | - | - | + | - | ||||||||
|
| - | - | + | 50% | - | ||||||||
|
| + | - | - | 60% | + | - | |||||||
| OC | - | - | - | 25% | - | + f | + | + | - | + | + | ||
|
| - | - | - | 90% | |||||||||
|
| + | + | - | 20% | + | + (focal) | |||||||
|
| + | +f | - | 20% | + | ||||||||
|
| + | + | - | 20% | + | + | |||||||
|
| + | +f | - | 35% | + | + | |||||||
|
| + | + | - | + | + | ||||||||
|
| + | 60% | - | + | |||||||||
|
| - | - | - | +f | + | ||||||||
|
| + | - | - | + | |||||||||
|
| + | + | 20% | + | + | +f | |||||||
|
| + | + | - | 60% | - | + | + | + | |||||
|
| + | + | - | 40% | - | + | +f |
ER= Estrogen-receptor; +f = focal, Mgbl= mammaglobin; OC= our case; PR=progesterone receptor, Ref= reference; S= synaptophysin; AR = androgen receptor; EMA = epithelial membrane antingen; + = Positive.